tetano
Editor, Senior Moderator
Npj Viruses
. 2024 Dec 30;2(1):68.
doi: 10.1038/s44298-024-00083-9. Automated and virus variant-programmable surrogate test qualitatively compares to the gold standard SARS-CoV-2 neutralization assay
Danielle W Ali[SUP] 1 [/SUP], Maggie L Bartlett[SUP] 1 [/SUP], Christopher D Heger[SUP] 2 [/SUP], Francisco Ramirez[SUP] 2 [/SUP], Linwood Johnson[SUP] 1 [/SUP], Kevin L Schully[SUP] 3 [/SUP], Eric D Laing[SUP] 4 [/SUP], Wei Wang[SUP] 5 [/SUP], Carol D Weiss[SUP] 5 [/SUP], Emilie Goguet[SUP] 4 6 [/SUP], Christopher C Broder[SUP] 4 [/SUP], Stephanie A Richard[SUP] 6 7 [/SUP], Nusrat J Epsi[SUP] 6 7 [/SUP], Brian Agan[SUP] 7 [/SUP], David Tribble[SUP] 7 [/SUP], Mark P Simons[SUP] 7 [/SUP], Timothy H Burgess[SUP] 7 [/SUP], Edward Mitre[SUP] 4 [/SUP], Simon Pollett[SUP] 6 7 [/SUP], Darci R Smith[SUP] 8 [/SUP]
Affiliations
The ongoing emergence of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants underscores the need for rapid, adaptable, high-throughput testing. However, assays for neutralizing antibodies, which are a good measure of viral protection, usually require cell culture and either infectious SARS-CoV-2 or pseudotyped viral particles. To circumvent the challenges of cell-based assays, SARS-CoV-2 surrogate virus neutralization tests (sVNTs) measure inhibition of the binding of the spike (S) protein receptor binding domain (RBD) to its receptor, human angiotensin-converting enzyme 2 (hACE2) by neutralizing antibodies. Here we tested a prototype automated microfluidic cartridge-based sVNT platform using SARS-CoV-2 wild-type (WT) and B.1.617.2 (Delta) variant RBDs. This sVNT showed a high correlation with cell-based neutralization assays for biospecimens collected post-COVID-19 vaccination and post-SARS-CoV-2 infection as well as for pre-pandemic SARS-CoV-2 negative sera. Thus, this assay, which takes less than 80 min, is a relatively simple, safe, and accurate alternative to traditional VNTs.
. 2024 Dec 30;2(1):68.
doi: 10.1038/s44298-024-00083-9. Automated and virus variant-programmable surrogate test qualitatively compares to the gold standard SARS-CoV-2 neutralization assay
Danielle W Ali[SUP] 1 [/SUP], Maggie L Bartlett[SUP] 1 [/SUP], Christopher D Heger[SUP] 2 [/SUP], Francisco Ramirez[SUP] 2 [/SUP], Linwood Johnson[SUP] 1 [/SUP], Kevin L Schully[SUP] 3 [/SUP], Eric D Laing[SUP] 4 [/SUP], Wei Wang[SUP] 5 [/SUP], Carol D Weiss[SUP] 5 [/SUP], Emilie Goguet[SUP] 4 6 [/SUP], Christopher C Broder[SUP] 4 [/SUP], Stephanie A Richard[SUP] 6 7 [/SUP], Nusrat J Epsi[SUP] 6 7 [/SUP], Brian Agan[SUP] 7 [/SUP], David Tribble[SUP] 7 [/SUP], Mark P Simons[SUP] 7 [/SUP], Timothy H Burgess[SUP] 7 [/SUP], Edward Mitre[SUP] 4 [/SUP], Simon Pollett[SUP] 6 7 [/SUP], Darci R Smith[SUP] 8 [/SUP]
Affiliations
- PMID: 40295688
- DOI: 10.1038/s44298-024-00083-9
The ongoing emergence of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants underscores the need for rapid, adaptable, high-throughput testing. However, assays for neutralizing antibodies, which are a good measure of viral protection, usually require cell culture and either infectious SARS-CoV-2 or pseudotyped viral particles. To circumvent the challenges of cell-based assays, SARS-CoV-2 surrogate virus neutralization tests (sVNTs) measure inhibition of the binding of the spike (S) protein receptor binding domain (RBD) to its receptor, human angiotensin-converting enzyme 2 (hACE2) by neutralizing antibodies. Here we tested a prototype automated microfluidic cartridge-based sVNT platform using SARS-CoV-2 wild-type (WT) and B.1.617.2 (Delta) variant RBDs. This sVNT showed a high correlation with cell-based neutralization assays for biospecimens collected post-COVID-19 vaccination and post-SARS-CoV-2 infection as well as for pre-pandemic SARS-CoV-2 negative sera. Thus, this assay, which takes less than 80 min, is a relatively simple, safe, and accurate alternative to traditional VNTs.